About ATI

Autonomic Technologies, Inc. (ATI) is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache. The company’s initial product, the Pulsante™ SPG Microstimulator System (ATI Neurostimulation System), is CE-marked in Europe for the relief of acute pain of cluster headache.

ATI’s neurostimulation system was voted #2 among the Cleveland Clinic’s top 10 medical innovations for 2013, and Autonomic Technologies was named one of ‘FierceMedicalDevices’ Fierce 15 most promising privately held medical device and diagnostics companies in the world.

ATI, a Cleveland Clinic Innovations spinoff, is located in the San Francisco Bay Area and is backed by blue chip investors Edmond de Rothschild Investment Partners, Forbion Capital Partners, HBM Healthcare Investments Ltd , Kleiner Perkins Caufield and Byers, InterWest Partners, Versant Ventures, Novartis Ventures, Aberdare Ventures & Cleveland Clinic

MDMA
 
© 2012-2015 Autonomic Technologies, Inc. All Rights Reserved. Last updated: 08 January 2015
CE Marked Intended Use: The Pulsante™ SPG Microstimulator System (ATI Neurostimulation System) is CE marked in Europe and is intended to relieve the acute pain of cluster headache. In some patients the use of the System has been associated with a reduction in the number of cluster headaches.
In the United States please note: Caution–Investigational device; limited by US law to investigational use.